|本期目录/Table of Contents|

[1]王学文.EB病毒淋巴增殖的治疗进展[J].医学研究与战创伤救治(原医学研究生学报),2010,12(04):325-329.
点击复制

EB病毒淋巴增殖的治疗进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第12卷
期数:
2010年04期
页码:
325-329
栏目:
综述
出版日期:
2010-07-20

文章信息/Info

Title:
-
文章编号:
1672-271X(2010)04-0325-05
作者:
王学文
210002 江苏南京，南京军区南京总医院血液病科
Author(s):
-
关键词:
EB病毒; 淋巴增殖性疾病; 细胞毒T细胞; 单克隆抗体; 化疗
Keywords:
-
分类号:
R730.3
DOI:
-
文献标志码:
A
摘要:
EB病毒(EBV)相关的B细胞淋巴增殖是造血干细胞或实体瘤移植后威胁生命的并发症，由于感染EBV的B细胞过度生长，正常由EBV细胞毒T细胞控制。在既往数十年中，采取系列测定外周血标本EBV-DNA负荷，以辅助确定高危患者和早期诊断淋巴增殖。治疗选择包括调控过度生长的、感染EBV的B细胞和EBV细胞毒T细胞反应间的平衡和采取靶向B细胞单克隆抗体或化疗。主要挑战仍然是为了确定优先治疗的指征与综合新的和常规的治疗。
Abstract:
-

参考文献/References:

[1]Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues［M］. Lyon:IARC Press, 2008:233-268.
[2］Cohen JM, Cooper N, Chakrabarti S, et al. EBV related disease following haematopoietic stem cell transplantation with reduced intensity conditioning［J］.Leuk Lymphoma,2007,48(2):256-269.
[3］Smith JM, Corey L, Healey PJ, et al. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients［J］. Transplantation,2007,83(11):1423-1428.
[4］Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia［J］. Bone Marrow Transplant, 2009,43(10):757-770.
[5］Lee TC, Savoldo B, Rooney CM, et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients［J］. Am J Transplant, 2005,5(9):2222-2228.
[6］Annels NE, Kalpoe JS, Bredius RG, et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV specific T cell reconstitution［J］. Clin Infect Dis,2006,42(12):1743-1748.
[7］Swinnen LJ, Leblanc M, Grogan TM, et al. Prospective study of sequential reduction in immunosuppression,interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder［J］. Transplantation, 2008,86(2):215-222.
[8］Bonini C, Bondanza A, Perna SK, et al. The suicide gene therapy challenge: how to improve a successful gene therapy approach［J］. Mol Ther,2007,15(7):1248-1252.
[9］Gottschalk S,Rooney CM,Heslop HE.Post-transplant lymphoproliferative disorders［J］.Ann Rev Med,2005,56(1):29-44.
[10］Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation［J］.Am J Transplant,2007,7(6):1648-1655.
[11］OReilly RJ, Doubrovina E, Trivedi D, et al. Adoptive transfer of antigenspecific T-cells of donor type for immunotherapy of viral infections following allogeneic hematopoietic cell transplants［J］. Immunol Res,2007,38(1):237-250.
[12］Savoldo B, Goss JA, Hammer MM, et al. Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)［J］. Blood,2006,108(9): 2942-2949.
[13］Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial ［J］. Blood,2007,110(4):1123-1131.
[14］Brunstein CG, Weisdorf DJ, Defor T, et al.Marked increased risk of Epstein-Barr virusrelated complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation［J］. Blood,2006,108(8):2874-2880.
[15］Blaes AH, Peterson BA, Bartlett N, et al. Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial［J］. Cancer,2005,104(8):1661-1667.
[16］Oertel SH, Verschuuren E, Reinke P, et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)［J］. Am J Transplant,2005,5(12):2901-2906.
[17］Choquet S, Leblond V, Herbrecht R, et al. Efficacy and safety of rituximab in B-cell posttransplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study［J］.Blood, 2006,107(8):3053-3057.
[18］Choquet S, Oertel S, Leblond V, et al. Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation:proceed with caution［J］. Ann Hematol,2007，86(8):599-607.
[19］Feng WH, Israel B, Raab-Traub N, et al.. Chemotherapy induces lytic EBV replication and confers ganciclovir susceptibility to EBV-positive epithelial cell tumors［J］. Cancer Res,2002,62(6):1920-1926.
[20］Perrine SP, Hermine O, Small T, et al. A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies［J］. Blood, 2007,109(6):2571-2578.
[21］Choquet S, Trappe R, Leblond V, et al.CHOP-21 for the treatment of posttransplant lymphoproliferative disorders (PTLD) following solid organ transplantation［J］. Haematologica,2007,92(2):273-274.
[22］Trappe R, Riess H, Babel N, et al. Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab［J］. Transplantation, 2007,83(7):912-918.
[23］Williams KM, Higman MA, Chen AR, et al. Successful treatment of a child with late-onset T-cell post-transplant lymphoproliferative disorder/lymphoma［J］.Pediatr Blood Cancer,2008,50(3):667-670.
[24］Gross TG, Bucuvalas JC, Park JR, et al. Lowdose chemotherapy for Epstein-Barr viruspositive post-transplantation lymphoproliferative disease in children after solid organ transplantation［J］. J Clin Oncol, 2005,23(27):6481-6488.
[25］Reshef R, Tsai DE. Rituximab for PTLD of the CNS: is it a “no-brainer?”［J］. Onkologie, 2008, 31(12):650-651.
[26］Cohen JM, Sebire NJ, Harvey J, et al. Successful treatment of lymphoproliferative disease complicating primary immunodeficiency/immunodysregulatory disorders with reduced-intensity allogeneic stem-cell transplantation［J］. Blood，2007,110(6):2209-2214.

相似文献/References:

[1]王茜,戴婷婷,耿建,等.EB病毒相关组织细胞坏死性淋巴结炎的临床分析[J].医学研究与战创伤救治(原医学研究生学报),2018,20(04):406.[doi:10.3969/j.issn.1672-271X.2018.04.018]

备注/Memo

备注/Memo:
-
更新日期/Last Update: 2010-07-20